Blood Reviews
Volume 24, Issue 4 , Pages 151-162 , July 2010

Anticoagulation in neonates and children: Pitfalls and dilemmas

  • Paul Monagle

      Affiliations

    • Department of Clinical Haematology, Royal Children's Hospital, Australia
    • Department of Paediatrics, The University of Melbourne, Australia
    • Haematology Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Flemington Rd, Parkville, Victoria 3052, Australia
    • Corresponding Author InformationCorresponding author. Royal Children's Hospital, Flemington Rd., Parkville, Melbourne, Victoria 3052, Australia. Tel.: +61 3 9345 5914; fax: +61 3 9349 1819.
    • ,
  • Fiona Newall

      Affiliations

    • Department of Clinical Haematology, Royal Children's Hospital, Australia
    • Department of Paediatrics, The University of Melbourne, Australia
    • Haematology Research Group, Murdoch Children's Research Institute, Royal Children's Hospital, Flemington Rd, Parkville, Victoria 3052, Australia
    • Department of Nursing, University of Melbourne, Australia
    • Tel.: +61 3 9345 5914; fax: +61 3 9349 1819.
    • ,
  • Janine Campbell

      Affiliations

    • Department of Clinical Haematology, Royal Children's Hospital, Australia
    • Tel.: +61 3 9345 5914; fax: +61 3 9349 1819.

References 

  1. Andrew M, Brooker L, Mitchell L. Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis. 1994;5(Suppl 1):S24–S36discussion S59–64
  2. Schmidt B, Andrew M. Neonatal thrombosis: Report of a prospective Canadian and international registry. Pediatrics. 1995;96(5 Pt 1):939–943
  3. Nowak-Gottl U, Dubbers A, Kececioglu D, Koch HG, Kotthoff S, Runde J, et al. Factor V Leiden, protein C, and lipoprotein (a) in catheter-related thrombosis in childhood: A prospective study. J Pediatr. 1997;131(4):608–612
  4. Baird CW, Zurakowski D, Robinson B, Gandhi S, Burdis-Koch L, Tamblyn J, et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: Impact of activated clotting time and heparin dose on survival. Ann Thorac Surg. 2007;83(3):912–919discussion 919-20
  5. Gibson B, Chalmers E, Bolton-Maggs P, Henderson D, Lynne R. Thrombembolism in childhood: A prospective 2year BPSU study in the United Kingdom. Thromb Haemost. 2003;1(Suppl1):OC422
  6. deVeber G, Chan A, Monagle P, Marzinotto V, Armstrong D, Massicotte P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: A cohort study. Arch Neurol. 1998;55(12):1533–1537
  7. Andrew M, Monagle P, Brooker L. Arterial thromboembolic complications in pediatric patients. In: Thromboembolic complications during infancy and childhood. Hamilton, B.C: Decker Inc; 2000;p. 165–200
  8. Kettner SC, Pollak A, Zimpfer M, Seybold T, Prusa AR, Herkner K, et al. Heparinase-modified thrombelastography in term and preterm neonates. Anesth Analg. 2004;98(6):1650–1652
  9. Dager WE, White RH. Low-molecular-weight heparin-induced thrombocytopenia in a child. Ann Pharmacother. 2004;38(2):247–250
  10. Fraser CJ, Newall F, Furmedge J, Campbell J, Savoia H, Monagle PT. Acute idiopathic portal vein thrombosis in a child: A case report and literature review. Thromb Res. 2006;117(3):279–281
  11. Nowak-Gottl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res. 2001;103(3):165–172
  12. Kuhle S, Koloshuk B, Marzinotto V, Bauman M, Massicotte P, Andrew M, et al. A cross-sectional study evaluating post-thrombotic syndrome in children. Thromb Res. 2003;111(4–5):227–233
  13. Coombs CJ, Richardson PW, Dowling GJ, Johnstone BR, Monagle P, Coombs CJ, et al. Brachial artery thrombosis in infants: An algorithm for limb salvage. Plast Reconstr Surg. 2006;117(5):1481–1488
  14. Newall F, Johnston L, Ignjatovic V, Summerhayes R, Monagle P. Age-related plasma reference ranges for two heparin binding proteins — vitronectin and platelet factor 4. Int J Lab Hematol. 2009;31(6):683–687
  15. Newall F, Savoia H, Campbell J, Monagle P. Anticoagulation clinics for children achieve improved warfarin management. Thromb Res. 2004;114(1):5–9
  16. Newall F, Johnston L, Monagle P. A survey of pediatric cardiology nurses' understanding of warfarin therapy. Pediatr Cardiol. 2006;27(2):204–208
  17. Massicotte P, Leaker M, Marzinotto V, Adams M, Freedom R, Williams W, et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost. 1998;80(4):570–574
  18. Monagle P, Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest. 2001;119(1 Suppl):344S–370S
  19. Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, et al. Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. Blood. 1999;94(9):3007–3014
  20. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: The REVIVE trial. Thromb Res. 2003;109(2–3):85–92
  21. Newall F, Campbell J, Savoia H, Barnes C, Monagle P. Incidence of major bleeding in a large paediatric cohort of patients requiring warfarin therapy. J Thromb Haemost. 2005;3(Suppl 1):OR357
  22. Ries M, Klinge J, Rauch R. Erfahrungen mit der antikoagulatientherapie bei 10 patienten an der Univ Kinderklinik Erlangen, in Thrombosen im Kindersalter. In:  Sutor AH editors. Basel: Editiones Roche; 1992;
  23. Taybi H, Capitanio MA. Tracheobronchial calcification: An observation in three children after mitral valve replacement and warfarin sodium therapy. Radiology. 1990;176(3):728–730
  24. Barnes C, Newall F, Ignjatovic V, Wong P, Cameron F, Jones G, et al. Reduced bone density in children on long-term warfarin. Pediatr Res. 2005;57(4):578–581
  25. Massicotte P, Julian J, Webber C. Osteoporosis: A potential complication of long term warfarin therapy. Thromb Haemost. 1999;Supply:1333a
  26. Marzinotto V, Monagle P, Chan A, Adams M, Massicotte P, Leaker M, et al. Capillary whole blood monitoring of oral anticoagulants in children in outpatient clinics and the home setting. Pediatr Cardiol. 2000;21(4):347–352
  27. Massicotte P, Marzinotto V, Vegh P, Adams M, Andrew M. Home monitoring of warfarin therapy in children with a whole blood prothrombin time monitor. J Pediatr. 1995;127(3):389–394
  28. Newall F, Bauman M. Point-of-care antithrombotic monitoring in children. Thromb Res. 2006;118(1):113–121
  29. Nowatzke WL, Landt M, Smith C, Wilhite T, Canter C, Luchtman-Jones L. Whole blood international normalization ratio measurements in children using near-patient monitors. J Pediatr Hematol Oncol. 2003;25(1):33–37
  30. Greenway A, Ignjatovic V, Summerhayes R, Newall F, Burgess J, DeRosa L, et al. Point-of-care monitoring of oral anticoagulation therapy in children. Comparison of the CoaguChek XS system with venous INR and venous INR using an International Reference Thromboplastin preparation (rTF/95). Thromb Haemost. 2009;102(1):159–165
  31. Hirsh J. Oral anticoagulant drugs. N Engl J Med. 1991;324(26):1865–1875
  32. Monagle P, Barnes C, Ignjatovic V, Furmedge J, Newall F, Chan A, et al. Developmental haemostasis impact for clinical haemostasis laboratories. Thromb Haemost. 2006;95(2):362–372
  33. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, et al. Monitoring unfractionated heparin (UFH) therapy: Which anti factor Xa assay is appropriate?. Thromb Res. 2006;120(3):347–351
  34. Ignjatovic V, Summerhayes R, Than J, Gan A, Monagle P. Therapeutic range for unfractionated heparin therapy: Age-related differences in response in children. J Thromb Haemost. 2006;4(10):2280–2282
  35. Ignjatovic V, Straka E, Summerhayes R, Monagle P. Age-specific differences in binding of heparin to plasma proteins. J Thromb Haemost. 2010;8(6):1290–1294
  36. Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, et al. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost. 2010;103(5):
  37. Newall F, Cranswick N, Ignjatovic V, Johnston L, Lane G, Summerhayes R, et al. Unfractionated heparin pharmacokinetic profile in children, in XXII Congress, International Society on Thrombosis and Haemostasis. 2009;Boston
  38. Andrew M, Marzinotto V, Massicotte P, Blanchette V, Ginsberg J, Brill-Edwards P, et al. Heparin therapy in pediatric patients: A prospective cohort study. Pediatr Res. 1994;35(1):78–83
  39. Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Mitchell LG. A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: A prospective cohort study. Haematologica. 2007;92(2):244–247
  40. Avioli LV. Heparin-induced osteopenia: An appraisal. Adv Exp Med Biol. 1975;52:375–387
  41. Murphy MS, John PR, Mayer AD, Buckels JA, Kelly DA. Heparin therapy and bone fractures. Lancet. 1992;340(8827):1098
  42. Schuster J, Meier-Ruge W, Egli F. Pathology of osteopathy following heparin therapy. Dtsch Med Wochenschr. 1969;94(45):2334–2338
  43. Sackler JP, Liu L. Heparin-induced osteoporosis. Br J Radiol. 1973;46(547):548–550
  44. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia*. Chest. 2008;133(6 suppl):340S–380S
  45. Klement D, Rammos S, v Kries R, Kirschke W, Kniemeyer HW, Greinacher A. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr. 1996;155(1):11–14
  46. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost. 1993;70(4):554–561
  47. Murdoch IA, Beattie RM, Silver DM. Heparin-induced thrombocytopenia in children. Acta Paediatr. 1993;82(5):495–497
  48. Potter C, Gill JC, Scott JP, McFarland JG. Heparin-induced thrombocytopenia in a child. J Pediatr. 1992;121(1):135–138
  49. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost. 2001;27(3):293–299
  50. Boshkov L, Ibsen L, Kirby A, Ungerleider RIS. Heparin-induced thrombocytopenia (HIT) in neonates and very young children undergoing congenital cardiac surgery: A likely under-recognized complication with significant morbidity and mortality: Report of 4 sequential cases. J Thromb Haemost. 2003;1(Suppl1):1494a
  51. Etches W, Stang L, Conradi A. Incidence of heparin-induced thrombocytopenia in a pediatric intensive care population. Blood. 2003;102(Suppl):536a
  52. Klenner AF, Fusch C, Rakow A, Kadow I, Beyersdorff E, Eichler P, et al. Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: A placebo-controlled trial. J Pediatr. 2003;143(6):741–745
  53. Newall F, Barnes C, Ignjatovic V, Monagle P. Heparin-induced thrombocytopenia in children. J Paediatr Child Health. 2003;39(4):289–292
  54. Schmugge M, Risch L, Huber AR, Benn A, Fischer JE. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics. 2002;109(1):E10
  55. Spadone D. Heparin induced thrombocytopenia in the newborn. J Vasc Surg. 1996;15:306–312
  56. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia?. Am J Hematol. 2007;82(12):1037–1043
  57. Klenner A, G.A. . Heparin-induced thrombocytopenia in children. In:  Warkentin T,  Greinacher A editor. Heparin-induced thrombocytopenia. 3rd ed. New York, NY: Marcel Dekker Inc; 2004;p. 553–571
  58. Risch L, Fischer JE, Herklotz R, Huber AR. Heparin-induced thrombocytopenia in paediatrics: Clinical characteristics, therapy and outcomes. Intensive Care Med. 2004;30(8):1615–1624
  59. Saxon BR, Black MD, Edgell D, Noel D, Leaker MT. Pediatric heparin-induced thrombocytopenia: Management with Danaparoid (orgaran). Ann Thorac Surg. 1999;68(3):1076–1078
  60. Severin T, Zieger B, Sutor AH. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost. 2002;28(5):447–454
  61. Chan VH, Monagle P, Massicotte P, Chan AK. Novel paediatric anticoagulants: a review of the current literature. Blood Coagul Fibrinolysis. 2010;21(2):144–151
  62. Galant SP. Accidental heparinization of a newborn infant. Am J Dis Child. 1967;114(3):313–319
  63. Glueck HI, Light IJ, Flessa H, Sutherland JM. Inadvertent sodium heparin administration to a newborn infant. JAMA. 1965;191:1031–1032
  64. Moncino MD, Kurtzberg J. Accidental heparinization in the newborn: A case report and brief review of the literature. J Perinatol. 1990;10(4):399–402
  65. Pachman DJ. Accidental heparin poisoning in an infant. Am J Dis Child. 1965;110:210–212
  66. Pegelow CH, Powars D. Inadvertent heperanization as a complication of intensive care. Clin Res. 1975;23:161A
  67. Schreiner RL, Wynn RJ, McNulty C. Accidental heparin toxicity in the newborn intensive care unit. J Pediatr. 1978;92(1):115–116
  68. US Food Drug Administration . FDA drug safety communication: Update: Follow up to the public health alert about changes to the heparin sodium USP monograph. In: Postmarket drug safety information for patients and providers. 2010;15/04/2010 [cited 22/04/2010]; Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm207506.htm
  69. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998;114(5 Suppl):489S–510S
  70. Michelson AD, Bovill E, Monagle P, Andrew M. Antithrombotic therapy in children. Chest. 1998;114(5 Suppl):748S–769S
  71. Bontadelli J, Moeller A, Schmugge M, Kretschmar O, Bauersfeld U, Schraner T, et al. Use of enoxaparin in the treatment of catheter-related arterial thrombosis in infants with congenital heart disease. Cardiol Young. 2006;16(Supplement 2):27
  72. Burak CR, Bowen MD, Barron TF. The use of enoxaparin in children with acute, nonhemorrhagic ischemic stroke. Pediatr Neurol. 2003;29(4):295–298
  73. Dix D, Andrew M, Marzinotto V, Charpentier K, Bridge S, Monagle P, et al. The use of low molecular weight heparin in pediatric patients: A prospective cohort study. J Pediatr. 2000;136(4):439–445
  74. Dix D, Charpentier K, Sparling C, et al. Determining of trough anti-factor Xa levels in pediatric patients on low molecular weight heparin (LMWH). J Pediatr Hematol Oncol. 1998;20(4):398
  75. Dunaway KK, Gal P, Ransom JL. Use of enoxaparin in a preterm infant. Ann Pharmacother. 2000;34(12):1410–1413
  76. Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S, et al. Prophylactic therapy with enoxaparin during l-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis. 2001;12(5):367–370
  77. Revel-Vilk S, Sharathkumar A, Massicotte P, Marzinotto V, Daneman A, Dix D, et al. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: A longitudinal study by ultrasound. J Thromb Haemost. 2004;2(1):42–46
  78. Schobess R, During C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Gottl U. Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: An open-label pilot study of once-daily versus twice-daily enoxaparin administration. Haematologica. 2006;91(12):1701–1704
  79. Streif W, Goebel G, Chan AK, Massicotte MP. Use of low molecular mass heparin (enoxaparin) in newborn infants: A prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed. 2003;88(5):F365–F370
  80. Kuhle S, Massicotte MP, Andrew M. A dose-finding study of Tinzaparin in pediatric patients. Blood. 2002;100:279a
  81. Massicotte MP, Adams M, Leaker M. A normogram to establish therapeutic levels of low molecular weight heparin (LMWH), clivarine in children requiring treatment for venous thromboembolism (VTE). Thromb Haemost. 1997;Supplement:1–843
  82. Nohe N, Flemmer A, Rumler R, Praun M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: A report on 48 cases. Eur J Pediatr. 1999;158(Suppl 3):S134–S139
  83. Chan AK, Berry LR, Monagle PT, Andrew M. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haemost. 2002;87(4):606–613
  84. Ignjatovic V, Summerhayes R, Newall F, Monagle PT. The in vitro response to low-molecular-weight heparin is not age-dependent in children. Thromb Haemost. 2010;103(4):
  85. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, et al. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: The PROTEKT trial. Thromb Res. 2003;109(2–3):101–108
  86. Malowany JI, Monagle P, Knoppert DC, Lee DS, Wu J, McCusker P, et al. Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates. Thromb Res. 2008;122(6):826–830
  87. Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P. Dosing and monitoring of enoxaparin (LMWH) therapy in children. Br J Haematol. 2010;149(5):734–738
  88. Massicotte P, Adams M, Marzinotto V, Brooker LA, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: A dose finding study. J Pediatr. 1996;128(3):313–318
  89. Bradley L, Midgley F, Watson D, Getson P, Scott L. Anticoagulation therapy in children with mechanical prosthetic cardiac valves. Am J Cardiol. 1985;56(8):533–535
  90. Doyle JJ, Koren G, Cheng MY, Blanchette VS. Anticoagulation with sodium warfarin in children: Effect of a loading regimen. J Pediatr. 1988;113(6):1095–1097
  91. Andrew M, David M, Adams M, Ali K, Anderson R, Barnard D, et al. Venous thrombotic complications (VTE) in children; first analysis of the Canadian registry of VTE. Blood. 1994;83(5):1251–1257
  92. Tait RC, Ladusans EJ, El-Metaal M, Patel RG, Will AM. Oral anticoagulation in paediatric patients: Dose requirements and complications. Arch Dis Child. 1996;74(3):228–231
  93. Cheung YF, Leung MP. Low dose oral anticoagulation therapy in Chinese children with congenital heart disease. J Paediatr Child Health. 1998;34(6):563–567
  94. Soper J, Chan GT, Skinner JR, Spinetto HD, Gentles TL. Management of oral anticoagulation in a population of children with cardiac disease using a computerised system to support decision-making. Cardiol Young. 2006;16(3):256–260
  95. Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP, et al. Acenocoumarol therapy in pediatric patients. J Thromb Haemost. 2003;1(8):1740–1743
  96. Woods A, Vargas J, Berri G, Kreutzer G, Meschengieser S, Lazzari MA. Antithrombotic therapy in children and adolescents. Thromb Res. 1986;42(3):289–301
  97. Ekert H, Seshadri R. Heparin treatment in childhood and its effect on monitoring tests. Aust Paediatr J. 1973;9(5):269–275
  98. Freed MD, Keane JF, Rosenthal A. The use of heparinization to prevent arterial thrombosis after percutaneous cardiac catheterization in children. Circulation. 1974;50(3):565–569
  99. McDonald M, Hathaway W. Anticoagulation therapy by continuous heparinization in newborn and older infants. J Pediatr. 1982;101(3):
  100. von Kries R, Stannigel H, Gobel U. Anticoagulant therapy by continuous heparin-antithrombin III infusion in newborns with disseminated intravascular coagulation. Eur J Pediatr. 1985;144(2):191–194
  101. Netz H, Madu B, Rohner G. Heparinization during percutaneous cardiac catheterization in children. Pediatr Cardiol. 1987;8(3):167–168
  102. Grady RM, Eisenberg PR, Bridges ND. Rational approach to use of heparin during cardiac catheterization in children. J Am Coll Cardiol. 1995;25(3):725–729
  103. Saxena A, Gupta R, Kumar RK, Kothari SS, Wasir HS. Predictors of arterial thrombosis after diagnostic cardiac catheterization in infants and children randomized to two heparin dosages. Catheter Cardiovasc Diagn. 1997;41(4):400–403
  104. Codispoti M, Ludlam CA, Simpson D, Mankad PS. Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg. 2001;71(3):922–927discussion 927–8
  105. Nankervis CA, Preston TJ, Dysart KC, Wilkinson WD, Chicoine LG, Welty SE, et al. Assessing heparin dosing in neonates on venoarterial extracorporeal membrane oxygenation. ASAIO J. 2007;53(1):111–114
  106. Guzzetta NA, Bajaj T, Fazlollah T, Szlam. F, Wilson E, Kaiser A, et al. A comparison of heparin management strategies in infants undergoing cardiopulmonary bypass. Anesth Analg. 2008;106(2):419–425table of contents
  107. Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, et al. Monitoring unfractionated heparin (UFH) therapy: Which anti-factor Xa assay is appropriate?. Thromb Res. 2007;120(3):347–351
  108. Newall F, Ignjatovic V, Summerhayes R, Gan A, Butt W, Johnston L, et al. In vivo age dependency of unfractionated heparin in infants and children. Thromb Res. 2009;123(5):710–714
  109. Hofmann S, Knoefler R, Lorenz N, Siegert G, Wendisch J, Mueller D, et al. Clinical experiences with low-molecular weight heparins in pediatric patients. Thromb Res. 2001;103(5):345–353
  110. Strater R, Kurnik K, Heller C, Schobess R, Luigs P, Nowak-Gottl U. Aspirin versus low-dose low-molecular-weight heparin: Antithrombotic therapy in pediatric ischemic stroke patients: A prospective follow-up study. Stroke. 2001;32(11):2554–2558
  111. Massicotte P, Julian JA, Marzinotto V, Gent M, Shields K, Chan AK, et al. Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. Thromb Res. 2003;109(2–3):93–99
  112. Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost. 2005;94(6):1164–1171

PII: S0268-960X(10)00026-3

doi: 10.1016/j.blre.2010.06.003

Blood Reviews
Volume 24, Issue 4 , Pages 151-162 , July 2010

Article Tools